Benefit of adding pioglitazone to statin therapy in non-diabetic patients with the metabolic syndrome

Wisconsin Medical Journal

Volumn 105, Issue 5, 2006, Pages 22-25

  Murdock, David K ^a,b   Jansen, Darlaen ^b   Juza, Ryan M ^b   Kersten, Mary ^a   Olson, Karen ^b,d   Hendricks, Bryan ^c  

^a Cardiovascular Associates of Northern Wisconsin   (United States)

^b Cardiovasc Res/Educ (CaRE) Found   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOTRANSFERASE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUINDOSTATIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROCHLOROTHIAZIDE; LIPID; MEVINOLIN; PIOGLITAZONE; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; STATIN; THIAZIDE DIURETIC AGENT; TRIACYLGLYCEROL;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; COST BENEFIT ANALYSIS; DIABETES MELLITUS; DRUG EFFECT; FEMALE; HEALTH CENTER; HUMAN; MALE; METABOLIC SYNDROME X; MONOTHERAPY; PERIPHERAL EDEMA; TREATMENT DURATION;

EID: 33747118373     PISSN: 10981861     EISSN: 10981861     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Deedwania PC, Hunninghake DB, Bays HE, Jones PH, Cain VA, Blasetto JW, STELLAR Study Group. Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome. Am J Cardiol. 2005;95:360-366.
2. Ayyobi AF, Brunzell JD. Lipoprotein distribution in the metabolic syndrome, type 2 diabetes mellitus, and familial combined hyperlipidemia. Am J Cardiol. 2003;92:27J-33J.
3. Xydakis AM, Ballantyne CM. Management of metabolic syndrome: statins. Endocrinol Metab Clin N Am. 2004;33:509-523.
4. Jones PH. Statins as the cornerstone of drug therapy for dyslipidemia: monotherapy and combination therapy options. Am Heart J. 2004;148(1 Suppl):S9-13.
5. Grundy SM. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med. 1988;319:24-33.
6. Murdock DK, Murdock AK, Murdock RW, et al. Long-term safety and efficacy of combination gemofibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders. Am Heart J. 1999;138:151-155.
7. Streja D. Combination therapy for the treatment of dyslipidemia. Curr Opin Investig Drugs. 2004;5:306-312.
8. Xydakis AM, Ballantyne CM. Combination therapy for combined dyslipidemia. Am J Cardiol. 2002;90:21K-29K.
9. Chang JT, Staffa JA, Parks M, Green L. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy. Pharmacoepidemiol Drug Saf. 2004;13:417-426.
10. Olansky L, Marchetti A, Lau H. Multicenter retrospective assessment of thiazolidinedione monotherapy and combination therapy in patients with type 2 diabetes: comparative subgroup analyses of glycemic control and blood lipid levels. Clin Ther. 2003;25:64-80.
11. Giannini S, Serio M, Galli A. Pleiotropic effects of thiazolidinediones: taking a look beyond antidiabetic activity. J Endocrinol Invest. 2004;27:982-991.
12. Gurnell M. PPARgamma and metabolism: insights from the study of human genetic variants. Clin Endocrinol. 2003;59:267-277.
13. Rajagopalan R, Iyer S, Khan M. Effect of pioglitazone on metabolic syndrome risk factors: results of double-blind, multicenter, randomized clinical trials. Curr Med Res Opin. 2005;21:163-172.
14. Szapary PO, Bloedon LT, Samaha FF, et al. Effects of pioglitazone on lipoproteins, inflammatory markers and adipokines in nondiabetic patients with metabolic syndrome. Arterioscler Thromb Vasc Biol. 2006:26:182-188.
15. Executive Summary. The third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001;285(19):2486-2497.
16. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997:20:1183-1197.
17. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
18. Demacker PN, Toenhake-Dijkstra H, de Rijke YB, Stalenhoef AF, Stuyt PM, Willems HL. On the presumed inaccuracy of the Friedewald formula in hypertriglyceridemic plasma: a role for imprecise analysis? Clin Chem. 1996;42:1491-1494.
19. Henry, JB. Clinical Diagnosis and Management by Laboratory Methods. 17th ed. Philadelphia, PA: WB Saunders; 1984:168-169.
20. Goldberg RB, Kendall DM, Deeg MA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care. 2005;28:7.
21. Holstein A, Egberts EH. Risk of hypoglycaemia with oral antidiabetic agents in patients with Type 2 diabetes. Exp Clin Endocrinol Diabetes. 2003;111:405-414.
22. Bogacka I, Xie H, Bray GA, Smith SR. The effect of pioglitazone on peroxisome proliferator-activated receptor-y target genes related to lipid storage in vivo. Diabetes Care. 2004;27:1660-1667.
23. Dormandy JA, Charbonnel B, Eckland DJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279-1289.